Status:

WITHDRAWN

An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease

Lead Sponsor:

Bristol-Myers Squibb

Conditions:

Non-Small Cell Lung Cancer

Non-Small-Cell Lung Carcinoma

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this study is to determine if nivolumab added to the standard of care therapy (SOC) given after surgery is more effective than SOC alone in prolonging disease free survival in NSCLC par...

Eligibility Criteria

Inclusion

  • Inclusion Criteria prior to Surgery:
  • Suspected or histologically confirmed Stage IIA to IIIB NSCLC with disease that is considered resectable
  • Must be deemed eligible for complete resection and must agree to undergo standard of care surgery for complete resection of NSCLC
  • Treatment naive (no previous systemic treatment)
  • Inclusion Criteria prior to Treatment Randomization:
  • Must have undergone complete surgical resection of their Stage IIA to IIIB NSCLC
  • Must have adequately recovered from surgery at the time of randomization
  • Minimal residual disease (MRD) positive results as detected by ctDNA
  • Exclusion Criteria prior to Surgery:
  • Participants with known EGFR mutations which are sensitive to available targeted inhibitor therapy (Prior to treatment randomization in select sites)
  • Active, known or suspected autoimmune disease
  • Participants with a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization
  • Exclusion Criteria prior to Treatment Randomization:
  • Must continue to meet Exclusion Criteria prior to Surgery
  • Must have no evidence of metastatic disease after surgery
  • Received a live/attenuated vaccine within 30 days of first treatment
  • Other protocol defined inclusion/exclusion criteria apply

Exclusion

    Key Trial Info

    Start Date :

    January 15 2021

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    March 14 2024

    Estimated Enrollment :

    Patients enrolled

    Trial Details

    Trial ID

    NCT03770299

    Start Date

    January 15 2021

    End Date

    March 14 2024

    Last Update

    March 24 2022

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

    An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease | DecenTrialz